The principal research question is whether the ingestion of stevia (rebaudioside A) in encapsulated format will have any effects on blood glucose, appetite and food intake in healthy human volunteers.
Obesity presents a major global health crisis; developing healthier diets is a key goal. Excess consumption of caloric sweeteners contributes to the alarming high rates of overweight and obesity. Non-nutritive sweeteners, like stevia, are used to decrease energy content of foods and beverages. Very recently a systematic review and meta-analysis conducted and published by WHO, concluded that non-nutritive sweeteners use results in small reduction in body weight and BMI in adults, as assessed in RCTs. In a previous set of studies from our group we showed that a single-dose of a stevia-sweetened beverage prior to lunch leads a lower energy intake compared to consuming water or a sugar-sweetened beverage (Stamataki et al J Nutr. 2020; 150(5):1126-1134. doi: 10.1093/jn/nxaa038). This effect was confirmed to be present in the long-term, as in another 12-weeks trial we demonstrated that individuals in the stevia group (they started consuming stevia drops twice daily with habitual drinks before their meals) demonstrated a significant spontaneous reduction in energy intake compared to the control group (Stamataki et al Nutrients. 2020;12(10):3049. doi: 10.3390/nu12103049). In a nutshell, this research so far has showed that stevia consumption elicits benefits in appetite and energy intake, without affecting physiological responses such as postprandial glucose response. Taking this research a step further, it is crucial now to answer whether sweetness without calories was the key component of these outcomes, in other words would stevia have the same effects if it was not tasted, if sweet taste (in the oral cavity) was bypassed? As such the main aim of this study is to evaluate the effects of stevia in a capsule vs placebo on appetite and energy intake and elucidate whether stevia elicits similar effects when sweet taste is bypassed.
Study Type
INTERVENTIONAL
Allocation
RANDOMIZED
Purpose
BASIC_SCIENCE
Masking
TRIPLE
Enrollment
17
rebaudioside A encapsulated in a vegetarian capsule
carboxymethylcellulose encapsulated in a vegetarian capsule
University of Manchester
Manchester, United Kingdom
Energy intake
Participants are allowed to eat from a buffet lunch until they feel comfortably full.
Time frame: Lunch at 30 min after the ingestion of the treatment
Appetite ratings
Using VAS scales for appetite, participants rate their appetite at baseline (before ingestion of the capsule), 15, 30 min after the ingestion of the capsule as well as at 60 min (which also corresponds 30 min after the start of the ad libitum meal).
Time frame: 0, 15, 30 and 60 min
Blood glucose
Capillary blood glucose measurements will be conducted at baseline (0), 15 min and 30 min following treatment as well as at 60 min after the ingestion of the capsule which also corresponds 30 min after the consumption of the ad libitum lunch.
Time frame: 0, 15, 30 and 60 min
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.